Phylex Biosciences

is a next-generation vaccine company uniquely located at
the crossroads of information technology and biotechnology.

We are developing the first booster mRNA vaccine against variants of concern of the SARS-CoV-2 coronavirus. Our vaccine is designed to protect against the omicron variant now prevalent worldwide and also against the delta variant, both responsible for increased transmissibility of COVID-19 and limited efficacy of current vaccines.